Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 6/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416773 | 0.95 | TGM2 (0.46) | TGM2ITGB1ITGA4ITGB7SIRT1 | |
| SCHEMBL13416909 | 0.88 | ITGB3 (0.44) | FOLH1 | |
| SCHEMBL13416667 | 0.88 | FAAH (0.45) | SIRT1FOLH1 | |
| SCHEMBL13416317 | 0.87 | TGM2 (0.38) | TGM2ITGB1ITGA4ITGB7SIRT1 | |
| SCHEMBL13417040 | 0.84 | NAALAD2 (0.43) | FOLH1GAA | |
| SCHEMBL13396841 | 0.83 | TGM2 (0.47) | TGM2ITGB1ITGA4ITGB7SIRT1 | |
| SCHEMBL13416587 | 0.83 | ITGB1 (0.39) | ITGB1ITGA4ITGB7TAAR1NPC1 | |
| SCHEMBL13416954 | 0.83 | ITGB3 (0.43) | TGM2FOLH1 | |
| SCHEMBL13416661 | 0.83 | FAAH (0.46) | SIRT1FOLH1 | |
| SCHEMBL13416308 | 0.82 | TGM2 (0.39) | TGM2ITGB1ITGA4ITGB7SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
| WO-2008095841-A2 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | TGM2 2807/4885ITGB1 253/4885ITGA4 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.